Want to join the conversation?
Neal Dingmann of SunTrust asks for an update on the Barnett. CEO Doug said, looking at the potential that $CHK has with the longer laterals and with economics that it is getting out of the other plays, the Barnett is not getting a lot of capital in the near term. He added that $CHK does not see directing capital there this year or in the near term.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.